Sonoma Pharmaceuticals (SNOA) Non Operating Interest Expenses (2010 - 2021)

Sonoma Pharmaceuticals has reported Non Operating Interest Expenses for 12 years, with the latest figure at $1000.0 in Q2 2021.

• On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $1000.0 in Q2 2021; TTM through Jun 2021 was $10000.0, a 66.67% increase from a year earlier, with the FY2021 full-year figure at $12000.0, down 25.0% from the prior year.
• Non Operating Interest Expenses was $1000.0 for Q2 2021 at Sonoma Pharmaceuticals, down from $5000.0 in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $208000.0 in Q3 2018, with the low at $1000.0 in Q1 2017.
• Average Non Operating Interest Expenses over 5 years is $18812.5, with a median of $7000.0 recorded in 2018.
• The sharpest annual moves came in 2018 and 2019: Non Operating Interest Expenses soared 1980.0% in 2018, then sank 99.04% in 2019.
• Over 5 years, Non Operating Interest Expenses stood at $11000.0 in 2017, then sank by 36.36% to $7000.0 in 2018, then sank by 85.71% to $1000.0 in 2019, then surged by 400.0% to $5000.0 in 2020, then tumbled by 80.0% to $1000.0 in 2021.
• The last three Non Operating Interest Expenses figures came in at $1000.0 (Q2 2021), $5000.0 (Q4 2020), and $4000.0 (Q3 2020), per Business Quant data.